LEADER 03907nam 2200853z- 450 001 9910557297603321 005 20231214132944.0 035 $a(CKB)5400000000041063 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/69163 035 $a(EXLCZ)995400000000041063 100 $a20202105d2020 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aBotulinum Toxin Treatment for Pain and Inflammation in Functional Urological Disorders 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2020 215 $a1 electronic resource (196 p.) 311 $a3-03936-670-X 311 $a3-03936-671-8 330 $aThe botulinum toxin has been widely applied in the treatment of functional urological diseases, such as overactive bladder, neurogenic detrusor overactivity, interstitial cystitis, and chronic pelvic pain syndrome. Evidence has shown that the botulinum toxin not only affects the release of neuropeptides from motor nerve endings, but also connects sensory nerves to the central nervous system. Inflammation in the central nervous system can be reduced after botulinum toxin treatment. The scope of therapeutic targets involves detrusor overactivity, sensory disorders, bladder pain and pelvic pain, and inflammatory disorders of the bladder, prostate, and bladder outlet. Although the actual pathophysiological mechanism of the action of the botulinum toxin has not been completely demonstrated, an anti-inflammation effect might be the predominant therapeutic mechanism for functional urological disorders such as an overactive bladder, bladder hypersensitivity, interstitial cystitis, chronic pelvic pain syndrome, chronic prostatitis, and lower urinary tract symptoms/benign prostatic hyperplasia. This Special Issue of Toxins covers the therapeutic potentials of the botulinum toxin on lower urinary tract dysfunctions, with emphasis on the mechanism of pharmacological action and clinical effects. 606 $aMedicine$2bicssc 610 $aurethra 610 $aonabotulinumtoxinA 610 $avoiding 610 $atherapeutic outcome 610 $alower urinary tract symptoms 610 $abotulinum toxin 610 $abenign prostatic hyperplasia 610 $aprostatitis 610 $ainflammation 610 $aBotulinum toxin 610 $achronic prostatitis 610 $ainterstitial cystitis 610 $atreatment 610 $abladder pain 610 $abotulinum toxin A 610 $apredictor 610 $amaximal bladder capacity 610 $ahydrodistention 610 $aurethral sphincter 610 $aurethral sphincter dysfunction 610 $aurodynamics 610 $adrug delivery 610 $aoveractive bladder 610 $apainful bladder syndrome 610 $amolecular mechanism 610 $achronic pelvic pain syndrome 610 $apelvic pain 610 $afunctional urology disorder 610 $ahuman 610 $anetwork meta-analysis 610 $aOnabotulinumtoxinA 610 $aperipheral tibial nerve stimulation 610 $asacral neuromodulation 610 $abladder 610 $asensation 610 $atherapy 610 $apathophysiology 610 $adiabetes mellitus 610 $amid-urethral sling 610 $aantimuscarinics 610 $aurinary incontinence 610 $afunctional urological disorders 610 $apain 610 $aneurogenic detrusor overactivity 615 7$aMedicine 700 $aKuo$b Hann-Chorng$4edt$01281276 702 $aKuo$b Hann-Chorng$4oth 906 $aBOOK 912 $a9910557297603321 996 $aBotulinum Toxin Treatment for Pain and Inflammation in Functional Urological Disorders$93018456 997 $aUNINA